MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
By MedImaging International staff writers Posted on 15 Mar 2024 |
MRI-guided focused ultrasound (MRgFUS) therapy is used by clinicians and interventional radiologists to precisely target specific areas for treatment, including prostate cancer. Previous studies have shown that this method can save more healthy tissue than traditional treatments, but the long-term effects of MRgFUS for prostate cancer have been unclear until now. A new study has demonstrated that MRgFUS is effective for treating intermediate-risk prostate cancer patients, with no negative side effects observed two years post-treatment.
In the single-center study, a research team at the University of Toronto (Ontario, Canada) conducted a study focusing on the two-year outcomes for men with intermediate-risk prostate cancer treated with transrectal MRgFUS from 2016 to 2019. The study involved 44 men, with a median age of 67, including 36 participants with a grade group of 2 and eight with a grade group of 3, indicating intermediate risk necessitating intervention. The treatment aimed to include a 10-mm margin around the target area whenever possible. Participants were asked to complete quality-of-life surveys six weeks after treatment and again at five, 12, 18, and 24 months. Information on any adverse events was also collected. To verify their results, the researchers conducted multiparametric MRI and both targeted and systematic biopsies at the 24-month mark.
The study found MRgFUS treatment to be highly successful, with no significant adverse events reported. One individual declined the biopsy at 24 months, but among the rest, 39 out of 43 (91%) showed no signs of clinically significant prostate cancer at the treated site, and 36 (84%) had no cancer throughout the entire gland two years later. Additionally, there were no significant changes in scores for erectile function or prostate symptoms over the two-year period, suggesting no decrease in the quality of life after undergoing MRgFUS treatment. These results support the broader use of MRgFUS for selected patients with intermediate-risk prostate cancer.
Related Links:
University of Toronto
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods